EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genomic Exploration of Distinct Molecular Phenotypes Steering Temozolomide Resistance Development in Patient-Derived Glioblastoma Cells

Federica Fabro iD, Trisha V Kers, Kate J Feller iD, Cecile Beerens, Ioannis Ntafoulis, Ahmed Idbaih iD, Maite Verreault iD, Kate Connor iD, Archita Biswas, Manuela Salvucci, Jochen H M Prehn, Annette T Byrne und 10 weitere

International Journal of Molecular Sciences · 27.10.2023 · 24 (21) · 15678

DOI: 10.3390/ijms242115678 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 27.10.2023. Verfasst von Federica Fabro und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery Rotterdam, Brain Tumor Center, Erasmus Medical Center Cancer Institute, Erasmus Medical Center, Wytemaweg 80, Ee2236, 3015…. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union's Horizon 2020 - Marie Skłodowska-Curie ITN, European Union’s Horizon 2020, Marie Skłodowska-Curie ITN initiative.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chemotherapy using temozolomide is the standard treatment for patients with glioblastoma. Despite treatment, prognosis is still poor largely due to the emergence of temozolomide resistance. This resistance is closely linked to the widely recognized inter- and intra-tumoral heterogeneity in glioblastoma, although the underlying mechanisms are not yet fully understood. To induce temozolomide resistance, we subjected 21 patient-derived glioblastoma cell cultures to Temozolomide treatment for a period of up to 90 days. Prior to treatment, the cells’ molecular characteristics were analyzed using bulk RNA sequencing. Additionally, we performed single-cell RNA sequencing on four of the cell cultures to track the evolution of temozolomide resistance. The induced temozolomide resistance was associated with two distinct phenotypic behaviors, classified as “adaptive” (ADA) or “non-adaptive” (N-ADA) to temozolomide. The ADA phenotype displayed neurodevelopmental and metabolic gene signatures, whereas the N-ADA phenotype expressed genes related to cell cycle regulation, DNA repair, and protein synthesis. Single-cell RNA sequencing revealed that in ADA cell cultures, one or more subpopulations emerged as dominant in the resistant samples, whereas N-ADA cell cultures remained relatively stable. The adaptability and heterogeneity of glioblastoma cells play pivotal roles in temozolomide treatment and contribute to the tumor’s ability to survive. Depending on the tumor’s adaptability potential, subpopulations with acquired resistance mechanisms may arise.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsHumansTemozolomideDacarbazineAntineoplastic Agents, AlkylatingCell Line, TumorPhenotypeGenomicsDrug Resistance, NeoplasmGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

glioblastomasingle-cell RNA sequencingtemozolomide resistancetumor heterogeneity

Substanzen

TemozolomideDacarbazineAntineoplastic Agents, Alkylating

Autor:innen und Institutionen

  • Department of Neurosurgery Rotterdam, Brain Tumor Center, Erasmus Medical Center Cancer Institute, Erasmus Medical Center, Wytemaweg 80, Ee2236, 3015 CN Rotterdam, The Netherlands.
  • Department of Molecular Genetics, Erasmus University Medical Center, 3015 CN Rotterdam, The Netherlands.
  • DMU Neurosciences, Service de Neurologie 2-Mazarin, Sorbonne Université, AP-HP, Institut du Cerveau-Paris Brain Institute-ICM, CNRS, University Hospital La Pitié Salpêtrière-Charles Foix, Inserm, F-75013 Paris, France.
  • Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, D02 YN77 Dublin, Ireland.
  • Department of Human Genetics, Laboratory for Translational Genetics, VIB Center for Cancer Biology, Katholieke Universiteit Leuven, 3000 Leuven, Belgium.
  • Information Technologies for Translational Medicine, L-4354 Esch-Sur-Alzette, Luxembourg.

ORCID-Profile: Federica Fabro, Kate J Feller, Ahmed Idbaih, Maite Verreault, Kate Connor, Alice C O'Farrell, Andreas Kremer, Miao-Ping Chien, Martine L M Lamfers

Förderung

  • European Union's Horizon 2020 - Marie Skłodowska-Curie ITN
  • European Union’s Horizon 2020
  • Marie Skłodowska-Curie ITN initiative

Zitieren

APA

Fabro, F., Kers, T. V., Feller, K. J., Beerens, C., Ntafoulis, I., Idbaih, A., Verreault, M., Connor, K., Biswas, A., Salvucci, M., Prehn, J. H. M., Byrne, A. T., O'Farrell, A. C., Lambrechts, D., Dilcan, G., Lodi, F., Arijs, I., Kremer, A., Tching Chi Yen, R., …, & Leenstra, S. (2023). Genomic Exploration of Distinct Molecular Phenotypes Steering Temozolomide Resistance Development in Patient-Derived Glioblastoma Cells. International Journal of Molecular Sciences, 24(21), 15678. https://doi.org/10.3390/ijms242115678

Vancouver

Fabro F, Kers TV, Feller KJ, Beerens C, Ntafoulis I, Idbaih A, et al. Genomic Exploration of Distinct Molecular Phenotypes Steering Temozolomide Resistance Development in Patient-Derived Glioblastoma Cells. International Journal of Molecular Sciences. 2023;24(21):15678. doi:10.3390/ijms242115678

BibTeX
@article{Fabro2023,
  author = {Fabro, Federica and Kers, Trisha V and Feller, Kate J and Beerens, Cecile and Ntafoulis, Ioannis and Idbaih, Ahmed and Verreault, Maite and Connor, Kate and Biswas, Archita and Salvucci, Manuela and Prehn, Jochen H M and Byrne, Annette T and O'Farrell, Alice C and Lambrechts, Diether and Dilcan, Gonca and Lodi, Francesca and Arijs, Ingrid and Kremer, Andreas and Tching Chi Yen, Romain and Chien, Miao-Ping and Lamfers, Martine L M and Leenstra, Sieger},
  title = {Genomic Exploration of Distinct Molecular Phenotypes Steering Temozolomide Resistance Development in Patient-Derived Glioblastoma Cells},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {21},
  pages = {15678},
  doi = {10.3390/ijms242115678}
}
Kostenlos starten →